Open Book Extracts (OBE) is now manufacturing hemp-derived cannabinol (CBN) isolate at scale.
Through a proprietary process, OBE is producing commercial quantities of bulk CBN at greater than 99% purity, making this rare cannabinoid widely available at the lowest cost on the market.
CBN is known for its potential to address concerns over sleep, stress and pain. OBE has successfully consolidated CBN production at the company’s headquarters in Roxboro, NC, allowing for further cost efficiencies and expanded production capacity powered by OBE’s cGMP operations and team of industry experts.
"OBE strives to be the cannabinoid enterprise of the future,” said OBE COO Scott Thorn. “We have put together a team committed to identifying forward-thinking technologies, and applying pharma grade R&D rigor to continuously develop and optimize methods for efficient, scaled cannabinoid production. You will see that commitment and tenacity woven into the fabric of everything we do, including most recently our commercial production of CBN and the forthcoming launch of additional high-demand products expected later this year."
OBE is producing kilogram quantities of 99 percent-plus pure CBN, currently available for bulk and wholesale purchase or under supply contract. In addition to CBN isolate, OBE distributes pure isolates of CBG, CBD and CBC; various THC-free broad-spectrum distillates, water soluble powders and liquids; and a portfolio of finished products including edibles, soft gels, tinctures and topical products. The company’s in-house formulation team can also support development of products for white label and private label manufacturing.
"Adding CBN to the OBE product portfolio aligns with the latest research supporting its therapeutic benefit and commercial readiness," says OBE CEO Dave Neundorfer. "This important milestone enables OBE to supply cGMP-certified CBN and high-quality finished products to our global customers. We continue to expand our offerings to correspond to the latest commercial demands and applications for cannabinoids, and the OBE team is determined to maintain the fast–paced development for which we are known."